See more : onesano S.A. (ONO.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Atreca, Inc. (BCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Atreca, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Palfinger AG (PLFRF) Income Statement Analysis – Financial Results
- Authentic Equity Acquisition Corp. (AEACW) Income Statement Analysis – Financial Results
- Bright Horizons Family Solutions Inc. (BFAM) Income Statement Analysis – Financial Results
- Precot Limited (PRECOT.NS) Income Statement Analysis – Financial Results
- Topcon Corporation (TOPCF) Income Statement Analysis – Financial Results
Atreca, Inc. (BCEL)
About Atreca, Inc.
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|
Revenue | 770.00K | 851.00K | 1.35M | 2.13M | 0.00 | 0.00 |
Cost of Revenue | 7.08M | 77.00K | 22.00K | 122.00K | 0.00 | 0.00 |
Gross Profit | -6.31M | 774.00K | 1.33M | 2.01M | 0.00 | 0.00 |
Gross Profit Ratio | -819.61% | 90.95% | 98.37% | 94.28% | 0.00% | 0.00% |
Research & Development | 66.83M | 78.35M | 62.05M | 54.73M | 32.51M | 24.87M |
General & Administrative | 31.47M | 31.95M | 26.83M | 17.85M | 7.06M | 4.56M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 31.47M | 31.95M | 26.83M | 17.85M | 7.06M | 4.56M |
Other Expenses | 770.00K | 851.00K | 1.35M | 2.13M | 961.00K | 1.72M |
Operating Expenses | 98.30M | 110.30M | 88.88M | 72.57M | 39.57M | 29.44M |
Cost & Expenses | 98.30M | 110.30M | 88.88M | 72.57M | 39.57M | 29.44M |
Interest Income | 817.00K | 207.00K | 1.22M | 3.21M | 714.00K | 152.00K |
Interest Expense | 0.00 | 3.00K | 4.00K | 6.00K | 9.00K | 14.00K |
Depreciation & Amortization | 7.08M | 4.55M | 2.38M | 1.70M | 1.41M | 1.21M |
EBITDA | -90.44M | -104.70M | -83.93M | -67.22M | -37.20M | -26.51M |
EBITDA Ratio | -12,559.48% | -12,837.25% | -6,203.33% | -3,150.14% | 0.00% | 0.00% |
Operating Income | -103.79M | -113.80M | -86.31M | -68.92M | -39.57M | -29.44M |
Operating Income Ratio | -13,479.09% | -13,371.92% | -6,379.01% | -3,229.66% | 0.00% | 0.00% |
Total Other Income/Expenses | 368.00K | 978.00K | 1.19M | 5.09M | 1.63M | 1.91M |
Income Before Tax | -97.16M | -109.33M | -86.33M | -67.48M | -37.94M | -27.52M |
Income Before Tax Ratio | -12,617.79% | -12,846.65% | -6,380.93% | -3,162.28% | 0.00% | 0.00% |
Income Tax Expense | -6.63M | 1.00K | 1.00K | 1.00K | -1.00K | 3.00K |
Net Income | -90.53M | -109.33M | -86.34M | -67.48M | -37.94M | -27.53M |
Net Income Ratio | -11,756.49% | -12,846.77% | -6,381.01% | -3,162.32% | 0.00% | 0.00% |
EPS | -2.35 | -2.95 | -2.70 | -4.26 | -11.75 | -12.44 |
EPS Diluted | -2.35 | -2.95 | -2.70 | -4.26 | -11.75 | -12.44 |
Weighted Avg Shares Out | 38.59M | 37.04M | 31.92M | 15.83M | 3.23M | 2.21M |
Weighted Avg Shares Out (Dil) | 38.59M | 37.04M | 31.92M | 15.83M | 3.23M | 2.21M |
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca Announces Poster Presentation at the Virtual American Association for Cancer Research (AACR) Annual Meeting
Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments
Atreca to Participate at Upcoming Virtual Investor Conferences
Atreca to Present at Upcoming Virtual Investor Conferences
NSW government wins battle to freeze pay of public servants for 12 months during pandemic
Western Union unterstützt Flüchtlinge aus dem Lager Moria
Cold weather brings new fears for struggling restaurant owners
Atreca (BCEL) Investor Presentation - Slideshow
Debt, reduced capacity top indie restaurant concerns
Source: https://incomestatements.info
Category: Stock Reports